3 recruiting. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow ASP2138: new trials by email Literature Review of ASP2138 trials Research Report on ASP2138
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 570 | 2026-07-28 | 2026-10-22 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer ASP2138, Oxaliplatin, Leucovorin - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 25 | 2025-10-16 | 2026-09-02 |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 398 | 2022-06-07 | 2026-09-11 |
Adenocarcinoma (2)
Astellas Pharma Global Development, Inc. (3)
United States (3) · China (2) · Japan (2) · Puerto Rico (2) · France (1) · Italy (1) · South Korea (1) · Spain (1)
2023 (1), 2025 (1)